Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company’s web site at www.momentapharma.com.
- 17 years ago
QualityStocks
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Issues Investor Update Highlighting Accelerated Revenue Growth, Global Partnerships, and Platform Expansion
Datavault AI (NASDAQ: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today…
-
QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of…
-
QualityStocksNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) to Host Webcast and Investor Q&A Following Q3 2025 Financial Results
Newton Golf Company (NASDAQ: NWTG), a technology-forward golf company focused on performance-driven innovation, today announced…